ArticleEClinicalMedicine2025
Age-specific chikungunya outbreak response immunisation strategies in Brazil: a modelling study.
Article in EClinicalMedicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors.
Funding
Abstract
Background: Two chikungunya vaccines, Ixchiq and Vimkunya are licensed. In April 2025, Brazil is the first endemic country to license Ixchiq, but optimal age groups for vaccination remain unclear. Our aim is to model the public health impact of age-specific chikungunya outbreak response immunisation strategies in Brazil and infer broader implications for vaccine use case scenarios in outbreak prone regions. Methods: We developed an age-structured transmission dynamic model calibrated with state-level Brazilian surveillance data for 2022 and long-term average annual force of infections. We simulated outbreak response immunisation strategies targeting ages 1-11, 12-17, 18-59, and ≥60 years for Ixchiq and Vimkunya across 11 out of 27 states in Brazil. We assessed vaccine impact by symptomatic cases, deaths, and disability-adjusted life years (DALYs) averted and number needed to vaccinate (NNV) based on vaccine protection against disease only and against both disease and infection. Findings: Ixchiq and Vimkunya showed similar vaccine impact. Across strategies, vaccinating children 1-11 years yielded the lowest NNV for both vaccines, whereas vaccinating adults 18-59 years achieved the greatest absolute reduction in symptomatic cases, averting 62.5% (95% Uncertainty Intervals [UI]: 54.2-84.1) of total symptomatic cases with Vimkunya and 66.2% (58.2-86.0) with Ixchiq, under disease and infection blocking mechanism. Vaccinating adults 18-59 years with Ixchiq or Vimkunya yielded similar efficiency, with NNVs to avert a DALY of 339 (39-3412) and 361 (40-3777) respectively, under disease and infection-blocking mechanism. Interpretation: Under current licensure, vaccinating adolescents aged 12-17 years first, followed by 18-59 years are efficient strategies, with similar NNVs for both Ixchiq and Vimkunya. If eligibility expands to younger populations, vaccinating 1-11-year age group will have relatively higher efficiency. Funding: International Vaccine Institute and Japan Agency for Medical Research and Development.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.